<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017623</url>
  </required_header>
  <id_info>
    <org_study_id>YH003003</org_study_id>
    <nct_id>NCT05017623</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Multicenter, Open-label, Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH003 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eucure (Beijing) Biopharma Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eucure (Beijing) Biopharma Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose-escalation study of the study drug YH003 . The study is designed&#xD;
      to determine the safety, tolerability and maximum tolerated dose (MTD) or recommended Phase 2&#xD;
      dose (RP2D) of YH003 in subjects with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>up to 1 year after the last dosing</time_frame>
    <description>The safety will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D)</measure>
    <time_frame>up to 1 year after the last dosing</time_frame>
    <description>The MTD and/or RP2D will be determined based on the data of safety and tolerability</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Intervention/treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH003</intervention_name>
    <description>All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.</description>
    <arm_group_label>Intervention/treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.Subject is willing and able to provide signed and dated informed consent prior to&#xD;
             all study-related procedures and is able to comply with all study procedures;&#xD;
&#xD;
          -  2.Patients with histologically or cytologically confirmed solid tumors who have failed&#xD;
             standard of care or have no standard of care;&#xD;
&#xD;
          -  3.Male or female, aged ≥ 18 years;&#xD;
&#xD;
          -  4.Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1;&#xD;
&#xD;
          -  5.Have life expectancy of at least 12 weeks based on investigator's judgement;&#xD;
&#xD;
          -  6.Subjects must meet the following laboratory values at the screening visit:&#xD;
&#xD;
             a）Absolute neutrophil count (ANC) ≥1.5 x 109/L (in absence of growth factor or other&#xD;
             support within 2 weeks prior to study entry) ; Platelet count ≥100 x 109/L;Hemoglobin&#xD;
             ≥9 g/dL or ≥ 5.6 mmol/L (without growth factor and transfusion support within 14 days&#xD;
             prior to study entry . b)Serum creatinine &lt; 1.5 × ULN, calculated creatinine clearance&#xD;
             (CrCL) &gt; 50 mL/min (Cockroft-Gault formula) or estimated glomerular filtration rate&#xD;
             (GFR) &gt; 50 mL/min; c)Aspartate aminotransferase (AST) and alanine aminotransferase&#xD;
             (ALT) and alkaline phosphatase ≤3.0 x ULN; AST or ALT ≤ 5 × ULN if liver metastases&#xD;
             are present; d) Serum total bilirubin (TBIL) ≤ 1.5 ULN (for patients with Gilbert's&#xD;
             syndrome, TBIL ≤ 3 × ULN); e)International normalized ratio (INR) ≤ 2.0 and activated&#xD;
             partial thromboplastin time (aPTT) ≤ 1.5 × ULN. Exception: INR 2 to ≤ 3 is acceptable&#xD;
             for subjects on Warfarin anticoagulation.&#xD;
&#xD;
          -  7.Women of reproductive potential who are sexually active with a non-sterilized male&#xD;
             must consistently use highly effective contraception/birth control between signing of&#xD;
             the informed consent and 120 days after the last administration of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Previous exposure to TNFR such as anti-CD137, OX40, CD27 and CD357 antibodies.&#xD;
&#xD;
          -  2.Patients with any other malignancy within the past 5 years or currently, except for&#xD;
             completely cured non-melanoma skin cancer, carcinoma in situ of the cervix, and ductal&#xD;
             carcinoma in situ of the breast;&#xD;
&#xD;
          -  3.Patients with hematological malignancies (such as acute lymphoblastic leukemia,&#xD;
             acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma, chronic&#xD;
             myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, etc.);&#xD;
&#xD;
          -  4.Subjects have received any anticancer therapy or another investigational agent&#xD;
             within the shorter of 4 weeks or 5 half-lives before the first dose of the study&#xD;
             treatment.Subjects have received Modern traditional Chinese medicine preparations with&#xD;
             anti-tumor effect approved by NMPA ≤ 2 weeks prior to first medication.Prior&#xD;
             palliative radiotherapy to bone metastases ≤ 2 weeks prior to the first dose of study&#xD;
             treatment is acceptable.&#xD;
&#xD;
          -  5.Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have&#xD;
             not recovered to ≤ Grade 1 per CTCAE 5.0, except alopecia,≤ Grade 2 sensory&#xD;
             neuropathy,lymphopenia, endocrine disease controlled by hormone replacement therapy;.&#xD;
&#xD;
          -  6.Subjects with a history of ≥ Grade 3 immune-related adverse events resulted from&#xD;
             previous immunotherapy or treatment discontinuation due to previous&#xD;
             immunotherapy.Except hypothyroidism, type 1 diabetes and dermatitis (excluding Steven&#xD;
             Johnson syndrome and toxic epidermal necrolysis);&#xD;
&#xD;
          -  7.History of clinically significant sensitivity or allergy to monoclonal antibodies&#xD;
             and their excipients or known allergies to antibodies produced from Chinese hamster&#xD;
             ovary cells&#xD;
&#xD;
          -  8.Primary central nervous system (CNS) malignancies or symptomatic CNS&#xD;
             metastases,except for the following. a) Subjects with asymptomatic brain metastases&#xD;
             (No progressive central nervous system symptoms caused by brain metastases, no need&#xD;
             for corticosteroids, and lesion size ≤ 1.5 cm);b)Subjects with stable lesions&#xD;
             confirmed by imaging examination after local treatment of brain metastases for ≥ 4&#xD;
             weeks, and who discontinued glucocorticoid or anticonvulsant drug treatment 2 weeks&#xD;
             before administration of the study drug;&#xD;
&#xD;
          -  9.History of non-infectious pneumonitis or interstitial lung disease that required&#xD;
             corticosteroids treatment , except for those caused by radiotherapy, or current&#xD;
             interstitial pneumonitis or pneumonitis; or history of other serious lung diseases;&#xD;
&#xD;
          -  10.History of active autoimmune disease, autoimmune disease requiring systemic&#xD;
             treatment, or history of autoimmune disease within 2 years prior to the first dose.&#xD;
             Exceptions are the following: vitiligo, childhood asthma/idiosyncratic reactions, etc.&#xD;
             for which alternative treatments are available;&#xD;
&#xD;
          -  11.Clinically uncontrolled intercurrent illness, including but not limit to&#xD;
             uncontrolled diabetes (blood glucose &gt; 250 mg/dl,1 mg/dl=18 mmol/L),uncontrolled&#xD;
             hypertension(Systolic blood pressure &gt; 150 mmHg or/and diastolic blood pressure &gt; 100&#xD;
             mmHg),History of hypertension or hypertensive encephalopathy; severe thyroid&#xD;
             dysfunction and other serious endocrine diseases or other serious diseases requiring&#xD;
             systemic treatment; active infection (such as active pulmonary tuberculosis); active&#xD;
             coagulation disorders; other serious diseases requiring systemic treatment;&#xD;
&#xD;
          -  12.Severe cardiovascular disease including symptomatic congestive heart failure (New&#xD;
             York Heart Association class III or IV), unstable angina,cardiac arrhythmia, a history&#xD;
             of myocardial infarction within 6 months or a history of arterial thromboembolic event&#xD;
             and pulmonary embolism within 3 months of the first dose of investigational agent.&#xD;
&#xD;
          -  13.QTc &gt; 470 ms at baseline; Concomitant medications that would prolong the QT&#xD;
             interval; Family history of long QT syndrome.&#xD;
&#xD;
          -  14.Subjects must not have active infection of human immunodeficiency virus, hepatitis&#xD;
             B, or hepatitis C&#xD;
&#xD;
          -  15. Subjects must not receive concurrent or prior use of an immunosuppressive agent&#xD;
             within 4 weeks of the first dose of YH003, with the following exceptions and&#xD;
             notes:a)Systemic steroids at physiologic doses (equivalent to dose of oral prednisone&#xD;
             10 mg) are permitted. b)Intranasal, inhaled, topical, intra-articular, and ocular&#xD;
             corticosteroids with minimal systemic absorption are permitted.&#xD;
&#xD;
          -  16.Major surgery within 4 weeks prior to study entry and Minor surgery within 2 weeks&#xD;
             prior to the first dose of YH003.&#xD;
&#xD;
          -  17.Subjects must not have received a live attenuated vaccine within 28 days before the&#xD;
             first dose of YH003, and subjects, if enrolled, should not receive live vaccines&#xD;
             during the study or for 180 days after the last dose of YH003.&#xD;
&#xD;
          -  18.Subjects who have had an allogeneic bone marrow transplant or organ transplant.&#xD;
&#xD;
          -  19.Subjects with psychiatric disorder, history of drug abuse, history of drug abuse,&#xD;
             or history of alcohol dependence that may affect trial compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lingqi Zhang</last_name>
    <phone>+86 010 85950770-8000</phone>
    <email>lingqi.zhang@eucure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen</last_name>
      <phone>0086-10-88196391</phone>
      <email>doctorshenlin@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

